Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tsuruha Holdings Inc. (3391.T)
JPY2,314.00
-46.50 (-1.97%)
JP JPX Healthcare Medical - Pharmaceuticals
Address
20-1-21, Kita 24 Johigashi 065-0024
Sapporo, JP
Sapporo, JP
CEO
Jun Tsuruha
Website
tsuruha-hd.co.jp
IPO
2001-02-22
ISIN JP3536150000
Also trades on
Other OTC · TSUSF (USD)
Tokyo Stock Exchange · 3391.T (JPY)
Description
Headquartered in Sapporo, Japan, Tsuruha Holdings Inc. is a retailer primarily engaged in managing a large chain of pharmacies throughout Japan. These establishments offer a comprehensive selection of medicinal and beauty products. As of October 15, 2021, the firm's retail footprint encompassed 2,448 stores within Japan, supplemented by an additional 22 locations in Thailand. The company's origins date back to its founding in 1929.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY2,314.00
-46.50 (-1.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.17
Float Shares
30.79M
Free Float %
63.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.02% | -3.78% | -4.20% | -24.90% | -28.80% | -31.43% | -12.80% | +1.31% | -25.88% | -13.15% | +995.28% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,314.00
DCF (Unlevered)
5,207.09
+125.0%
DCF (Levered)
6,390.85
+176.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
22% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 7 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.41
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+35.4% ★ Q2'26: +133.7% (vs Q2'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+60.7% ★ Q2'26: -34.7% (vs Q2'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+4.1% Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.8% Q2'26: +3.8% (vs Q2'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+5.2% Q2'26: +8.4% (vs Q2'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+21.4% Q2'26: +85.8% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.09× ★ Q2'26: 0.28× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Feb 2015 actual |
Feb 2016 actual |
Feb 2017 actual |
Feb 2018 actual |
Feb 2019 actual |
Feb 2020 actual |
Feb 2021 actual |
Feb 2022 actual |
Feb 2023 actual |
Feb 2024 actual |
Feb 2025 actual |
Feb 2026 7 Rev. Ana. 7 EPS Ana. |
Feb 2027 7 Rev. Ana. 8 EPS Ana. |
Feb 2028 7 Rev. Ana. 7 EPS Ana. |
Feb 2029 6 Rev. Ana. 6 EPS Ana. |
Feb 2030 3 Rev. Ana. 2 EPS Ana. |
Feb 2031 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
440.43B
est: 439.65B (+0.2%)
|
527.51B
est: 522.48B (+1.0%)
|
577.09B
est: 579.75B (-0.5%)
|
673.24B
est: 671.53B (+0.3%)
|
782.45B
est: 780.66B (+0.2%)
|
841.04B
est: 834.56B (+0.8%)
|
919.30B
est: 919.24B (+0.0%)
|
915.70B
est: 924.59B (-1.0%)
|
970.08B
est: 969.88B (+0.0%)
|
1.03T
est: 1.04T (-1.3%)
|
1.07T
est: 847.21B (+26.5%)
|
1.45T
1.45T – 1.46T
+71.4% YoY
|
2.55T
2.54T – 2.57T
+75.7% YoY
|
2.62T
2.59T – 2.65T
+2.9% YoY
|
2.71T
2.70T – 2.71T
+3.1% YoY
|
2.85T
2.82T – 2.87T
+5.2% YoY
|
2.95T
2.92T – 2.97T
+3.4% YoY
|
| EBITDA |
32.45B
est: 26.35B (+23.2%)
|
38.12B
est: 31.31B (+21.7%)
|
42.86B
est: 34.74B (+23.4%)
|
49.17B
est: 40.24B (+22.2%)
|
53.34B
est: 46.78B (+14.0%)
|
56.52B
est: 50.01B (+13.0%)
|
61.67B
est: 55.08B (+12.0%)
|
53.11B
est: 55.40B (-4.1%)
|
61.31B
est: 58.12B (+5.5%)
|
57.78B
est: 62.38B (-7.4%)
|
57.40B
est: 50.77B (+13.1%)
|
87.00B
86.66B – 87.19B
+71.4% YoY
|
152.85B
152.05B – 153.74B
+75.7% YoY
|
157.29B
155.29B – 159.09B
+2.9% YoY
|
162.17B
161.94B – 162.40B
+3.1% YoY
|
170.64B
169.10B – 172.12B
+5.2% YoY
|
176.50B
174.90B – 178.02B
+3.4% YoY
|
| EBIT |
26.90B
est: 18.43B (+45.9%)
|
31.32B
est: 21.90B (+43.0%)
|
35.28B
est: 24.30B (+45.2%)
|
40.24B
est: 28.15B (+43.0%)
|
41.83B
est: 32.72B (+27.8%)
|
45.01B
est: 34.98B (+28.7%)
|
48.38B
est: 38.53B (+25.6%)
|
38.45B
est: 38.75B (-0.8%)
|
44.76B
est: 40.65B (+10.1%)
|
39.78B
est: 43.63B (-8.8%)
|
37.81B
est: 35.51B (+6.5%)
|
60.85B
60.61B – 60.99B
+71.4% YoY
|
106.92B
106.35B – 107.54B
+75.7% YoY
|
110.02B
108.62B – 111.28B
+2.9% YoY
|
113.43B
113.27B – 113.60B
+3.1% YoY
|
119.36B
118.28B – 120.39B
+5.2% YoY
|
123.45B
122.34B – 124.52B
+3.4% YoY
|
| Net Income |
17.21B
est: 106.02B (-83.8%)
|
19.32B
est: 24.87B (-22.3%)
|
23.23B
est: 29.40B (-21.0%)
|
24.80B
est: 31.22B (-20.6%)
|
24.82B
est: 30.85B (-19.5%)
|
27.90B
est: 34.45B (-19.0%)
|
26.28B
est: 34.60B (-24.0%)
|
21.39B
est: 28.96B (-26.1%)
|
25.26B
est: 29.92B (-15.6%)
|
21.74B
est: 136.69B (-84.1%)
|
21.81B
est: 25.14B (-13.2%)
|
36.13B
32.46B – 39.79B
+43.7% YoY
|
30.69B
24.76B – 36.62B
-15.0% YoY
|
35.82B
31.12B – 40.51B
+16.7% YoY
|
42.29B
36.90B – 47.69B
+18.1% YoY
|
53.46B
52.83B – 54.06B
+26.4% YoY
|
60.12B
59.41B – 60.80B
+12.5% YoY
|
| SGA |
97.48B
est: 113.26B (-13.9%)
|
117.92B
est: 134.59B (-12.4%)
|
129.79B
est: 149.34B (-13.1%)
|
152.54B
est: 172.99B (-11.8%)
|
181.66B
est: 201.10B (-9.7%)
|
199.35B
est: 214.98B (-7.3%)
|
218.04B
est: 236.80B (-7.9%)
|
230.91B
est: 238.18B (-3.0%)
|
247.79B
est: 249.84B (-0.8%)
|
265.13B
est: 268.18B (-1.1%)
|
278.37B
est: 218.24B (+27.6%)
|
374.01B
372.52B – 374.84B
+71.4% YoY
|
657.11B
653.64B – 660.91B
+75.7% YoY
|
676.17B
667.59B – 683.92B
+2.9% YoY
|
697.15B
696.16B – 698.15B
+3.1% YoY
|
733.57B
726.95B – 739.93B
+5.2% YoY
|
758.74B
751.89B – 765.31B
+3.4% YoY
|
| EPS |
72.47
est: 358.01 (-79.8%)
|
81.15
est: 83.97 (-3.4%)
|
96.91
est: 99.29 (-2.4%)
|
103.05
est: 105.41 (-2.2%)
|
102.77
est: 104.16 (-1.3%)
|
115.37
est: 116.31 (-0.8%)
|
108.40
est: 116.83 (-7.2%)
|
88.12
est: 97.77 (-9.9%)
|
103.98
est: 101.05 (+2.9%)
|
89.45
est: 461.68 (-80.6%)
|
89.65
est: 80.41 (+11.5%)
|
126.15
109.61 – 134.36
+56.9% YoY
|
98.12
83.62 – 123.66
-22.2% YoY
|
121.44
105.09 – 136.80
+23.8% YoY
|
148.83
124.59 – 161.04
+22.6% YoY
|
180.50
178.38 – 182.53
+21.3% YoY
|
203.00
200.62 – 205.29
+12.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
44.59B
OE per share TTM
182.83
Owner's Yield
4.87%
Maintenance CapEx ratio
3.49%
Maint CapEx / Avg PPE
10.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 106 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree International Multifactor Fund DWMF | 0.26% | 89.2K | 0.38% |
| 2 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.21% | 1.20M | 0.58% |
| 3 | iShares MSCI Japan Small-Cap ETF SCJ | 0.21% | 538.0K | 0.50% |
| 4 | Invesco JPX-Nikkei 400 UCITS ETF N4US.L | 0.09% | 196.0K | 0.19% |
| 5 | Invesco JPX-Nikkei 400 UCITS ETF NS4E.DE | 0.09% | 195.5K | 0.19% |
| 6 | Invesco JPX-Nikkei 400 UCITS ETF N400.L | 0.09% | 195.6K | 0.19% |
| 7 | iShares JPX-Nikkei 400 ETF 1364.T | 0.09% | 3.40M | 0.05% |
| 8 | iShares JPX-Nikkei 400 ETF JPXN | 0.09% | 118.9K | 0.48% |
| 9 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.08% | 181.2K | 0.83% |
| 10 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.08% | 10.92M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
5.92M
Shares Outstanding
48.70M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jun Tsuruha | President, Chief Executive Officer & Representative Director | 106M | male |
| Kazuhiko Nomura | Executive Officer - Group Dispensing Management Department & GM of Dispensing Operations Division | — | — |
| Kei Wakabayashi | Head of Investor Relations & Budget Management Department | — | — |
| Kinone Takaomi | Executive Officer & GM of the HR Development Headquarters (Head of Group HR Development Division) | — | — |
| Masahiro Yawata | Executive Officer | — | male |
| Naotaka Kokawaji | Executive Officer | — | male |
| Norihito Ojima | Executive Officer - Group Human Resources and General Affairs Department & GM of HR and GA Division | — | — |
| Ryutaro Miyake | Executive Officer and GM of Accounting & Finance Division | — | — |
| Shoichi Murakami | Executive Officer | — | male |
| Toyama Kazuto | Executive Officer of Group Store Development Division, GM of Store Development Division & Director | — | male |
| Tsuyoshi Hanzawa | Executive Officer | — | male |
| Yasuyuki Arima | Executive Officer - Group Product Division | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3391.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
